Low levels of arsenite activates nuclear factor-κB and activator protein-1 in immortalized mesencephalic cells

Journal of Biochemical and Molecular Toxicology

Volumn 19, Issue 2, 2005, Pages 67-77

  Felix, Kumar ^a   Manna, Sunil K ^b   Wise, Kimberly ^a   Barr, Johnny ^a   Ramesh, Govindarajan T ^a  

^a TEXAS SOUTHERN UNIVERSITY   (United States)

^b CENTRE FOR DNA FINGERPRINTING AND DIAGNOSTICS   (India)

Author keywords

Activator protein 1 (AP 1); Arsenite; Electrophoretic mobility shift assay (EMSA); Extracellular signal regulated kinase (ERK); Nuclear factor kappa B (NF B); Reactive oxygen species (ROS)

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ARSENIC; ARSENIC TRIOXIDE; ARSENITE SODIUM; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRON; MANGANESE; METAL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR AP 1;

ARTICLE; CELL IMMORTALIZATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; ENZYME PHOSPHORYLATION; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; MESENCEPHALON; MONOAMINERGIC SYSTEM; NERVE DEGENERATION; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; SYMPTOMATOLOGY; TIME;

ANIMALS; ARSENITES; CELL LINE, TRANSFORMED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; MESENCEPHALON; NF-KAPPA B; SODIUM COMPOUNDS; TRANSCRIPTION FACTOR AP-1; UP-REGULATION;

EID: 17644384443     PISSN: 10956670     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbt.20062     Document Type: Article

References (92)

1. Waalkes MP, Fox DA, States JC, Patierno SR, McCabe MJ Jr. Metals and disorders of cell accumulation: Modulation of apoptosis and cell proliferation. Toxicol Sci 2000;56:255-261.
2. Hall AH. Chronic arsenic poisoning. Toxicol Lett 2002;128:69-72.
3. Golub MS, Macintosh MS, Baumrind N. Developmental and reproductive toxicity of inorganic arsenic: Animal studies and human concerns. J Toxicol Environ Health B Crit Rev 1998;1:199-241.
4. Lindgren A, Danielsson BR, Dencker L, Vahter M. Embryotoxicity of arsenite and arsenate: Distribution in pregnant mice and monkeys and effects on embryonic cells in vitro. Acta Pharmacol Toxicol (Copenh) 1984;54:311-320.
5. Nagaraja TN, Desiraju T. Regional alterations in the levels of brain biogenic amines, glutamate, GABA, and GAD activity due to chronic consumption of inorganic arsenic in developing and adult rats. Bull Environ Contam Toxicol 1993;50:100-107.
6. Valkonen S, Savolainen H, Jarvisalo J. Arsenic distribution and neurochemical effects in peroral sodium arsenite exposure of rats. Bull Environ Contam Toxicol 1983;30:303-308.
7. Beaudoin AR. Teratogenicity of sodium arsenate in rats. Teratology 1974;10:153-157.
8. Chaineau E, Binet S, Pol D, Chatellier G, Meininger V. Embryotoxic effects of sodium arsenite and sodium arsenate on mouse embryos in culture. Teratology 1990;41:105-112.
9. Ferm VH, Carpenter SJ. Malformations induced by sodium arsenate. J Reprod Fertil 1968;17:199-201.
10. Hood RD, Bishop SL. Teratogenic effects of sodium arsenate in mice. Arch Environ Health 1972;24:62-65.
11. Morrissey RE, Mottet NK. Arsenic-induced exencephaly in the mouse and associated lesions occurring during neurulation. Teratology 1983;28:399-411.
12. Tabocova S, Hunter ES III, Gladen BC. Developmental toxicity of inorganic arsenic in whole embryo: Culture oxidation state, dose, time, and gestational age dependence. Toxicol Appl Pharmacol 1996;138:298-307.
13. Wlodarczyk BJ, Bennett GD, Calvin JA, Finnell RH. Arsenic-induced neural tube defects in mice: Alterations in cell cycle gene expression. Reprod Toxicol 1996;10:447-454.
14. Mejia JJ, Diaz-Barriga F, Calderon J, Rios C, Jimenez-Capdeville ME. Effects of lead-arsenic combined exposure on central monoaminergic systems. Neurotoxicol Teratol 1997;19:489-497.
15. Rodriguez VM, Carrizales L, Jimenez-Capdeville ME, Dufour L, Giordano M. The effects of sodium arsenite exposure on behavioral parameters in the rat. Brain Res Bull 2001;55:301-308.
16. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
17. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it. Ann Neurol 1992;32:804-812.
18. Maker HS, Weiss C, Silides DJ, Cohen G. Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J Neurochem 1981;36:589-593.
19. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992;59:1609-1623.
20. Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978;14:33-43.
21. Hastings TG. Enzymatic oxidation of dopamine: The role of prostaglandin H synthase. J Neurochem 1995;64:919-924.
22. Earle KM. Studies on Parkinson's disease including x-ray fluorescent spectroscopy of formalin fixed brain tissue. J Neuropathol Exp Neurol 1968;27:1-14.
23. Dexter DT, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD. Increased nigral iron content in post-mortem parkinsonian brain. Lancet 1987;2:1219-1220.
24. Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991;114:1953-1975.
25. Gotz ME, Double K, Gerlach M, Youdim MB, Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 2004;1012:193-208.
26. Lai BC, Marion SA, Teschke K, Tsui JK. Occupational and environmental risk factors for Parkinson's disease. Park Relat Disord 2002;8:297-309.
27. Powers KM, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD, Checkoway H. Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology 2003;60:1761-1766.
28. Gorell JM, Peterson EL, Rybicki BA, Johnson CC. Multiple risk factors for Parkinson's disease. J Neurol Sci 2004;217:169-174.
29. Zayed J, Ducic S, Campanella G, Panisset JC, Andre P, Masson H, Roy M. Facteurs environnementaux dans l'etiologie de la maladie de Parkinson. Can J Neurol Sci 1990;17:286-291.
30. Ngim CH, Devathasan G. Epidemiologic study on the association between body burden mercury level and idiopathic Parkinson's disease. Neuroepidemiology 1989;8:128-141.
31. Seidler A, Hellenbrand W, Robra BP, Vieregge P, Nischan P, Joerg J, Oertel WH, Ulm G, Schneider E. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: A case-control study in Germany. Neurology 1996;46:1275-1284.
32. Logroscino G, Marder K, Graziano J, Freyer G, Slavkovich V, Lojacono N, Cote L, Mayeux R. Dietary iron, animal fats, and risk of Parkinson's disease. Mov Disord 1998;13:13-16.
33. Checkoway H. Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology 2003;60:1761-1766.
34. Leonard SS, Harris GK, Shi X. Metal-induced oxidative stress and signal transduction. Free Radic Biol Med 2004;37:1921-1942.
35. Shi H, Shi X, Liu KJ. Oxidative mechanism of arsenic toxicity and carcinogenesis. Mol Cell Biochem 2004;255:67-78.
36. Chen W, Martindale JL, Holbrook NJ, Liu Y. Tumor promoter arsenite activates extracellular signal-regulated kinase through a signaling pathway mediated by epidermal growth factor receptor and Shc. Mol Cell Biol 1998;18:5178-5188.
37. Gurr JR, Liu F, Lynn S, Jan KY. Calcium-dependent nitric oxide production is involved in arsenite-induced micronuclei. Mutat Res 1998;416:137-148.
38. Fuente H, Portales-Perez D, Baranda L, Diaz-Barriga F, Saavedra-Alanis V, Layseca E, Gonzalez-Amaro R. Effect of arsenic, cadmium and lead on the induction of apoptosis of normal human mononuclear cells. Clin Exp Immunol 2002;129:69-77.
39. Jiang XH, Wong BC, Yuen ST, Jiang H, Cho CH, Lai KC, Lin MC, Kung HF, Lam SK, Chun-Yu Wong B. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3. Int J Cancer 2001;91:173-179.
40. Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell RP Jr, Rafii S. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000;96:1525-1530.
41. Chen Y, Lin-Shiau SY, Lin J. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J Cell Physiol 1998;177:324-333.
42. Hei TK, Liu SX, Waldren C. Mutagenicity of arsenic in mammalian cells: Role of reactive oxygen species. Proc Natl Acad Sci U S A 1998;95:8103-8107.
43. Li M, Cai JF, Chiu JF. Arsenic induces oxidative stress and activates stress gene expressions in cultured lung epithelial cells. J Cell Biochem 2002;87:29-38.
44. Liu SX, Athar M, Lippai I, Waldren C, Hei TK. Induction of oxyradicals by arsenic: Implication for mechanism of genotoxicity. Proc Natl Acad Sci U S A 2001;98:1643-1648.
45. Nakagawa Y, Akao Y, Morikawa H, Hirata I, Katsu K, Naoe T, Ohishi N, Yag K. Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci 2002;70:2253-2269.
46. Chattopadhyay S, Bhaumik S, Purkayastha M, Basu S, Nag Chaudhuri A, Das Gupta S. Apoptosis and necrosis in developing brain cells due to arsenic toxicity and protection with antioxidants. Toxicol Lett 2002;136:65-76.
47. Chaudhuri AN, Basu S, Chattopadhyay S, Das Gupta S. Effect of high arsenic content in drinking water on rat brain. Indian J Biochem Biophys 1999;36:51-54.
48. Flora SJ. Arsenic-induced oxidative stress and its reversibility following combined administration of N-acetylcysteine and meso 2,3-dimercaptosuccinic acid in rats. Clin Exp Pharmacol Physiol 1999;26:865-869.
49. Snow ET. Metal carcinogenesis: Mechanistic implications. Pharmacol Ther 1992;53:31-65.
50. Porter A, Fanger G, Vaillancourt R. Signal transduction pathways regulated by arsenate and arsenite. Oncogene 1999;18:7794-7802.
51. Trouba KJ, Wauson EM, Vorce RL. Sodium arsenite-induced dysregulation of proteins involved in proliferative signaling. Toxicol Appl Pharmacol 2000;164:161-170.
52. Kapahi P, Takahashi T, Natoli G, Adams SR, Chen Y, Tsien RY, Karin M. Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem 2000;275:36062-36066.
53. Delhase M, Hayakawa M, Chen Y, Karin M. Positive and negative regulation of I kappa B kinase activity through IKK beta subunit phosphorylation. Science 1999;284:309-313.
54. Karin M, Delhase M. The I kappa B kinase (IKK) and NF-kappa B: Key elements of proinflammatory signalling. Semin Immunol 2000;12:85-98.
55. Hsu TC, Young MR, Cmarik J, Colburn NH. Activator protein 1 (AP-1)- and nuclear factor kappa B (NF-kappa B)-dependent transcriptional events in carcinogenesis. Free Radic Biol Med 2000;28:1338-1348.
56. Germolec DR, Yoshida T, Gaido K, Wilmer JL, Simeonova PP, Kayama F, Burleson F, Dong WM, Lange RW, Luster MI. Arsenic induces overexpression of growth factors in human keratinocytes. Toxicol Appl Pharmacol 1996;141:308-318.
57. Barchowsky A, Klei LR, Dudek EJ, Swartz HM, James PE. Stimulation of reactive oxygen, but not reactive nitrogen species, in vascular endothelial cells exposed to low levels of arsenite. Free Radic Biol Med 1999;27:1405-1412.
58. Parrish AR, Zheng XH, Turney KD, Younis HS, Gandolfi AJ. Enhanced transcription factor DNA binding and gene expression induced by arsenite or arsenate in renal slices. Toxicol Sci 1999;50:98-105.
59. Hu Y, Jin X, Snow ET. Effect of arsenic on transcription factor AP-1 and NF-kappa B DNA binding activity and related gene expression. Toxicol Lett 2002;133:33-45.
60. Qian Y, Castranova V, Shi X. New perspectives in arsenic-induced cell signal transduction. J Inorg Biochem 2003;96:271-278.
61. Clarkson ED, Edwards-Prasad J, Freed CR, Prasad KN. Immortalized dopamine neurons: A model to study neurotoxicity and neuroprotection. Proc Soc Exp Biol Med 1999;222:157-163.
62. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 1976;72:248-254.
63. Ramesh GT, Manna SK, Aggarwal BB, Jadhav AL. Lead exposure activates nuclear factor kappa B, activator protein-1, c-Jun N-terminal kinase and caspases in the rat brain. Toxicol Lett 2001;123:195-207.
64. Ramesh GT, Ghosh D, Gunasekar PG. Activation of early signaling transcription factor, NF-kappa B following low-level manganese exposure. Toxicol Lett 2002;136:151-158.
65. Lynn S, Gurr JR, Lai HT, Jan KY. NADH oxidase activation is involved in arsenite-induced oxidative DNA damage in human vascular smooth muscle cells. Circ Res 2000;86:514-519.
66. Corsini E, Asti L, Viviani B, Marinovich M, Galli CL. Sodium arsenate induces overproduction of interleukin-1 alpha in murine keratinocytes: Role of mitochondria. J Invest Dermatol 1999;113:760-765.
67. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999;94:2102-2111.
68. Wang TS, Kuo CF, Jan KY, Huang H. Arsenite induces apoptosis in Chinese hamster ovary cells by generation of reactive oxygen species. J Cell Physiol 1996;169:256-268.
69. Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 2003;101:4098-4104.
70. Nesnow S, Roop BC, Lambert G, Kadiiska M, Mason RP, Cullen WR, Mass MJ. DNA damage induced by methylated trivalent arsenicals is mediated by reactive oxygen species. Chem Res Toxicol 2002;15:1627-1634.
71. Chávez EG, Abel Santamaría A, Barriga FD, Mandeville P, Bertha I, Juárez BI, Capdeville MEJ. Arsenite-induced formation of hydroxyl radical in the striatum of awake rats. Brain Res 2003;976:82-89.
72. Chattopadhyay S, Bhaumik S, Nag Chaudhuri A, Das Gupta S. Arsenic induced changes in growth development and apoptosis in neonatal and adult brain cells in vivo and in tissue culture. Toxicol Lett 2002;128:73-84.
73. Kannan GM, Flora SJ. Chronic arsenic poisoning in the rat: Treatment with combined administration of succimers and an antioxidant. Ecotoxicol Environ Saf 2004;58:37-43.
74. Simeonova PP, Luster MI. Mechanisms of arsenic carcinogenicity: Genetic or epigenetic mechanisms. J Environ Pathol Toxicol Oncol 2000;19:281-286.
75. Pulido MD, Parrish AR. Metal-induced apoptosis: Mechanisms. Mutat Res 2003;533:227-241.
76. Huang C, Ke Q, Costa M, Shi X. Molecular mechanisms of arsenic carcinogenesis. Mol Cell Biochem 2004;255:57-66.
77. Karin M, Delhase M. JNK or IKK, AP-1 or NF-kappa B, which are the targets for MEK kinase 1 action? Proc Natl Acad Sci U S A 1998;95:9067-9069.
78. Roussel RR, Barchowsky A. Arsenic inhibits NF-kappa B-mediated gene transcription by blocking I kappa B kinase activity and I kappa B alpha phosphorylation and degradation. Arch Biochem Biophys 2000;377:204-212.
79. Tsai SH, Liang YC, Chen L, Ho FM, Hsieh MS, Lin JK. Arsenite stimulates cyclooxygenase-2 expression through activating IkappaB kinase and nuclear factor kappa B in primary and ECV304 endothelial cells. J Cell Biochem 2002;84:750-758.
80. Wijeweera JB, Gandolfi AJ, Parrish A, Lantz RC. Sodium arsenite enhances AP-1 and NF kappa B DNA binding and induces stress protein expression in precision-cut rat lung slices. Toxicol Sci 2001;61:283-294.
81. Ramesh GT, Manna SK, Aggarwal BB, Jadhav AL. Lead activates nuclear transcription factor-kappa B, activator protein-1, and amino-terminal c-Jun kinase in pheochromocytoma cells. Toxicol Appl Pharmacol 1999;155:280-286.
82. Chen F, Castranova V, Shi X, Demers LM. New insights into the role of nuclear factor-kappa B, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 1999;45:7-17.
83. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994;78:773-785.
84. Lee FS, Hagler J, Chen ZJ, Maniatis T. Activation of the I kappa B alpha kinase complex by MEKK1, a kinase of the JNK pathway. Cell 1997;88:213-222.
85. Huang C, Li J, Ding M, Wang L, Shi X, Castranova V, Vallyathan V, Ju G, Costa M. Arsenic-induced NF kappa B transactivation through Erks- and JNKs-dependent pathways in mouse epidermal JB6 cells. Mol Cell Biochem 2001;222:29-34.
86. Wise K, Manna S, Barr J, Gunasekar P, Ramesh G. Activation of activator protein-1 DNA binding activity due to low level manganese exposure in pheochromocytoma cells. Toxicol Lett 2004;147:237-244.
87. Wisdom R. AP-1: One switch for many signals. Exp Cell Res 1999;253:180-185.
88. Harris GK, Shi X. Signaling by carcinogenic metals and metal-induced reactive oxygen species. Mutat Res 2003;533:183-200.
89. Cavigelli M, Li WW, Lin A, Su B, Yoshioka K, Karin M. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J 1996;15:6269-6279.
90. Chen F, Ding M, Lu Y, Leonard SS, Vallyathan V, Castranova V, Shi X. Participation of MAP kinase p38 and I kappa B kinase in chromium (VI)-induced NF-kappa B and AP-1 activation. J Environ Pathol Toxicol Oncol 2000;19:231-238.
91. Bode AM, Dong Z. Chemotherapeutic effects. Crit Rev Oncol Hematol 2002;42:5-24.
92. Namgung U, Xia Z. Arsenic induces apoptosis in rat cerebellar neurons via activation of JNK3 and p38 MAP kinases. Toxicol Appl Pharmacol 2001;174:130-138.